Interleukin 7 - Revimmune SAS
Alternative Names: CYT 107; Glycosylated recombinant human interleukin-7 - Cytheris; IL-7; Recombinant human interleukin-7 - Cytheris; rhIL-7; Second-generation CYT 99 007Latest Information Update: 01 Aug 2024
At a glance
- Originator Cytheris
- Developer Cognate BioServices; Cytheris; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Revimmune SAS; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The French National Agency for Research on AIDS and Viral Hepatitis; University Hospital Limoges; Washington University School of Medicine
- Class Anti-infectives; Antibacterials; Antineoplastics; Antiretrovirals; Antivirals; Cytokines; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin 7 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Bladder cancer; Breast cancer; Colorectal cancer; HIV infections; Lymphopenia; Nontuberculous mycobacterium infections; Prostate cancer; Sepsis; Urogenital cancer
- Suspended Idiopathic CD4-positive T-lymphocytopenia
- Discontinued Bone marrow transplant rejection; Hepatitis B; Hepatitis C; Progressive multifocal leukoencephalopathy
Most Recent Events
- 26 Jul 2024 Washington University School of Medicine plans a phase I trial for Multiple myeloma (Second-line therapy or greater) in the US, in October 2024 (SC) (NCT06523699)
- 09 Apr 2024 Revimmune terminates phase-II IMPULSE-7 clinical trial in Nontuberculous mycobacterium infections (Treatment-experienced) in USA (IM) due to non convincing results (NCT04154826)
- 25 Jan 2024 Updated efficacy and adverse events data from a phase II trial in Urogenital cancer presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)